81 citations
,
February 2000 in “Anti-cancer drugs” In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.
6 citations
,
May 2008 in “Current Opinion in Oncology” This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.
August 2008 in “Current Opinion in Internal Medicine” This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.